Diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma: A meta-analysis


Autoři: Woojoo Lee aff001;  Eun Shin aff002;  Bo-Hyung Kim aff003;  Hyunchul Kim aff002
Působiště autorů: Department of Statistics, Inha University, Incheon, Republic of Korea aff001;  Department of Pathology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Republic of Korea aff002;  Department of Clinical Pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital, Seoul, Republic of Korea aff003;  Department of Biomedical Science and Technology, Graduate School, Kyung Hee University, Seoul, Republic of Korea aff004
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225096

Souhrn

SOX11 is a transcription factor that is normally expressed in the fetal brain and has also been detected in some malignant tumors, including mantle cell lymphoma (MCL). MCL is a mature B-cell lymphoma that characteristically expresses cyclin D1, which has been used as a diagnostic tumor marker. SOX11 has also recently emerged as a tumor marker for MCL, particularly in cyclin D1-negative MCLs and to distinguish between MCLs and other cyclin D1-positive lymphomas. In this study, we evaluated the diagnostic accuracy of SOX11 immunohistochemistry for the diagnosis of MCL using a meta-analysis. A comprehensive literature search was performed using the PubMED, EMBASE, and Cochrane library through May 9, 2018. In total, 14 studies were included in our meta-analysis. The sensitivity, specificity, and area under the curve calculated from the summary receiver operator characteristic were 0.9, 0.95, and 0.934, respectively. Effect sizes of log positive likelihood ratios, log negative likelihood ratios, and log diagnostic odds ratios were 2.67, -2.12, and 5.27, respectively. Statistically significant substantial heterogeneity was observed for specificity (I2 = 95%), but not for sensitivity. Subgroup analysis and meta-regression were performed to explain the heterogeneity in specificity and showed that the proportions of Burkitt’s lymphoma, lymphoblastic lymphoma, and hairy cell leukemia were significant covariates among studies using rabbit polyclonal antibodies. Overall, this meta-analysis showed that SOX11 was a useful diagnostic marker for MCL, with the clone MRQ-58 mouse monoclonal antibody showing particularly robust performance.

Klíčová slova:

Cancer detection and diagnosis – Cyclins – Immunohistochemistry techniques – Lymphomas – Monoclonal antibodies – Molecular cloning


Zdroje

1. Jay P, Goze C, Marsollier C, Taviaux S, Hardelin JP, Koopman P, et al. The human SOX11 gene: cloning, chromosomal assignment and tissue expression. Genomics. 1995;29(2):541–5. Epub 1995/09/20. doi: 10.1006/geno.1995.9970 8666406.

2. Brennan DJ, Ek S, Doyle E, Drew T, Foley M, Flannelly G, et al. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur J Cancer. 2009;45(8):1510–7. Epub 2009/03/11. doi: 10.1016/j.ejca.2009.01.028 19272768.

3. Harrison G, Hemmerich A, Guy C, Perkinson K, Fleming D, McCall S, et al. Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas. Am J Clin Pathol. 2017;149(1):67–75. Epub 2017/12/23. doi: 10.1093/ajcp/aqx142 29272888.

4. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, et al. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep. 2005;13(1):139–44. Epub 2004/12/08. 15583815.

5. Zhang LN, Cao X, Lu TX, Fan L, Wang L, Xu J, et al. Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas. Am J Clin Pathol. 2013;140(6):795–800. Epub 2013/11/15. doi: 10.1309/AJCPEBOUJ7GVYVLG 24225745.

6. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–62. Epub 2009/11/03. doi: 10.3324/haematol.2009.010264 19880778; PubMed Central PMCID: PMC2770966.

7. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised fourth edition. ed. Lyon, France Geneva, Switzerland: International Agency for Research on Cancer WHO Press; 2017. 585 pages p.

8. Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16(7):637–40. Epub 1992/07/01. doi: 10.1097/00000478-199207000-00001 1530105.

9. Jeon YK, Yoon SO, Paik JH, Kim YA, Shin BK, Kim HJ, et al. Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. J Pathol Transl Med. 2017;51(3):224–41. Epub 2017/05/26. doi: 10.4132/jptm.2017.04.09 28535584; PubMed Central PMCID: PMC5445208.

10. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121(8):1394–402. Epub 2012/12/21. doi: 10.1182/blood-2012-08-452284 23255553; PubMed Central PMCID: PMC3578954.

11. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315–21. Epub 2005/08/27. doi: 10.1182/blood-2005-04-1753 16123218; PubMed Central PMCID: PMC1895253.

12. Chuang WY, Chang H, Chang GJ, Wang TH, Chang YS, Wang TH, et al. Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology. 2017;70(6):986–99. doi: 10.1111/his.13161 28032914.

13. Hsiao SC, Cortada IR, Colomo L, Ye H, Liu H, Kuo SY, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology. 2012;61(4):685–93. Epub 2012/05/31. doi: 10.1111/j.1365-2559.2012.04260.x 22642745.

14. Dictor M, Ek S, Sundberg M, Warenholt J, Gyorgy C, Sernbo S, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009;94(11):1563–8. Epub 2009/11/03. doi: 10.3324/haematol.2009.008474 19880779; PubMed Central PMCID: PMC2770967.

15. Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36(2):214–9. Epub 2012/01/19. doi: 10.1097/PAS.0b013e318241f050 22251940.

16. Cao X, Fan L, Fang C, Zhu DX, Dong HJ, Wang DM, et al. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases. Medical oncology (Northwood, London, England). 2012;29(2):1190–6. Epub 2011/04/12. doi: 10.1007/s12032-011-9937-5 21479697.

17. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2010;23(1):105–12. Epub 2009/10/06. doi: 10.1038/modpathol.2009.140 19801969.

18. Hsi AC, Hurley MY, Lee SJ, Rosman IS, Pang X, Gru A, et al. Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas. Journal of cutaneous pathology. 2016;43(4):354–61. Epub 2016/01/15. doi: 10.1111/cup.12668 26762898.

19. Nakashima MO, Durkin L, Bodo J, Lin J, Quintanilla-Martinez L, Fu K, et al. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Applied immunohistochemistry & molecular morphology: AIMM. 2014;22(10):720–7. Epub 2014/09/18. doi: 10.1097/pai.0000000000000067 25229384.

20. Nordstrom L, Andreasson U, Jerkeman M, Dictor M, Borrebaeck C, Ek S. Expanded clinical and experimental use of SOX11—using a monoclonal antibody. BMC cancer. 2012;12:269. Epub 2012/06/29. doi: 10.1186/1471-2407-12-269 22738398; PubMed Central PMCID: PMC3495897.

21. Soldini D, Valera A, Sole C, Palomero J, Amador V, Martin-Subero JI, et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol. 2014;38(1):86–93. Epub 2013/10/23. doi: 10.1097/PAS.0b013e3182a43996 24145648.

22. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. 2008;143(2):248–52. Epub 2008/08/30. doi: 10.1111/j.1365-2141.2008.07329.x 18729857.

23. Zhang YH, Liu J, Dawlett M, Guo M, Sun X, Gong Y. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples. Cancer cytopathology. 2014;122(12):892–7. Epub 2014/07/25. doi: 10.1002/cncy.21465 25056830.

24. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. Epub 2003/11/11. doi: 10.1186/1471-2288-3-25 14606960; PubMed Central PMCID: PMC305345.

25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.

26. Schwarzer G. meta: An R package for meta-analysis. R News. 2007;7(3):40–5.

27. Doebler P. Meta-Analysis of Diagnostic Accuracy. R package version 0.5.8. https://CRAN.R-project.org/package=mada 2017.

28. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693–708. Epub 1999/10/16. doi: 10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v 10521860.

29. McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17(8):646–9. Epub 2002/09/06. doi: 10.1046/j.1525-1497.2002.10750.x 12213147; PubMed Central PMCID: PMC1495095.

30. Lord M, Wasik AM, Christensson B, Sander B. The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. Haematologica. 2015;100(9):e369–72. Epub 2015/04/19. doi: 10.3324/haematol.2015.123885 25887497; PubMed Central PMCID: PMC4800709.

31. Kimura Y, Sato K, Imamura Y, Arakawa F, Kiyasu J, Takeuchi M, et al. Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. Cancer Sci. 2011;102(9):1734–41. Epub 2011/05/26. doi: 10.1111/j.1349-7006.2011.01988.x 21609366.

32. Lee W, Shin E, Kim BH, Kim H. Inconsistency associated with SOX11 immunohistochemistry in mantle cell lymphoma: a meta-analysis. J Hematop. 2019;12(3):109–19. doi: 10.1007/s12308-019-00361-z WOS:000485312300002.


Článek vyšel v časopise

PLOS One


2019 Číslo 11